BioPharma Dive February 25, 2025
The Trump administration’s plans to reduce National Institutes of Health grant funding could have long-term consequences for the U.S. drug industry, investors said.
The biotechnology sector’s foundations rest on basic scientific research. Early experiments done in academic laboratories often yield the discoveries that venture investors later form drug startups around.
Investors and industry experts are concerned that system is under threat in the U.S., where the Trump administration has roiled the scientific community with actions disrupting funding provided by the National Institutes of Health to research institutes around the country. The administration has also imposed large-scale layoffs at the NIH and other health agencies like the Food and Drug Administration.
One of the most notable changes is a new NIH...
Today's Sponsors
Today's Sponsor